Drug Discovery Today 2011 v.16 №01-02

London, UK.: Elsevier. — 100 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Peter Wipfler, Andrea Harrer, Georg Pilz, Katrin Oppermann, Eugen Trinka and Jörg Kraus.
Angiotensin II receptors and drug discovery in cardiovascular disease.
Chiranjib Dasgupta and Lubo Zhang.
Gene to screen.
New avenues to target Wnt/ -catenin signaling.
Folkert Verkaar and Guido J.R. Zaman.
Nformatics.
Understanding infectious agents from an in silico perspective.
Joo Chuan Tong and Lisa F.P. Ng.
Post screen.
Creativity, innovation and lean sigma: a controversial combination?
Craig Johnstone, Garry Pairaudeau and Jonas A. Pettersson.
Characterization of protein therapeutics by mass spectrometry: recent developments and future directions.
Guodong Chen, Bethanne M. Warrack, Angela K. Goodenough, Hui Wei, David B. Wang-Iverson and Adrienne A. Tymiak.
The graphical representation of ADME-related molecule properties for medicinal chemists.
Timothy J. Ritchie, Peter Ertl and Richard Lewis.
Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
Harald E. Heemstra, Hubert G.M. Leufkens, R.P. Channing Rodgers, Kui Xu, Bettie C.G. Voordouw and M. Miles Braun.
Early chemical development at Legacy Wyeth Research.
Michael K. O’Brien, Michael Kolb, Terrence J. Connolly, J. Christopher McWilliams and Karen Sutherland.